Drug General Information (ID: DDIEYI629J)
Drug Name			Inotuzumab ozogamicin		Drug Info		Asenapine		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Atypical Antipsychotics

Mechanism of Inotuzumab ozogamicin-Asenapine Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Inotuzumab ozogamicin				Asenapine
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Asenapine

Recommended Action
Management		Coadministration of asenapine with other drugs that can prolong the QT interval should generally be avoided. Caution and clinical monitoring are recommended if concomitant use is required. Patients should have regular ECGs and be monitored for arrhythmias when QT interval is prolonged.

References
1	Canadian Pharmacists Association.
2	Cerner Multum, Inc. "Australian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
5	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".